Fred Aslan's most recent trade in Artiva Biotherapeutics Inc was a trade of 366,850 Common Stock done . Disclosure was reported to the exchange on Feb. 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2026 | 366,850 | 1,576,798 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.00 per share. | 15 Feb 2026 | 14,600 | 1,562,198 | - | 4 | 58,400 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 15 Dec 2025 | 3,187 | 1,209,948 | - | 6 | 19,122 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 869,136 | 1,213,135 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 319,331 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 257,319 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 113,999 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 100,577 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 51,463 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Dec 2025 | 26,450 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 3.38 per share. | 15 Nov 2025 | 6,375 | 343,999 | - | 3.4 | 21,522 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.25 per share. | 15 Nov 2025 | 6,347 | 350,374 | - | 3.3 | 20,628 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 17 Oct 2025 | 25,500 | 356,721 | - | 6 | 153,000 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.73 per share. | 15 May 2025 | 25,500 | 386,693 | - | 2.7 | 69,579 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.13 per share. | 15 May 2025 | 4,472 | 412,193 | - | 2.1 | 9,525 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. | 15 May 2025 | 4,472 | 382,221 | - | 2.8 | 12,298 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 200,000 | 416,665 | - | 0 | Common Stock | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 343,811 | 343,811 | - | - | Employee Stock Option (Right to Buy) | |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2024 | 228,905 | 228,905 | - | 0 | Common Stock |